Insulet: Omnipod Momentum Still Intact — Time a Long with a Defined Risk
Insulet’s Omnipod adoption and international expansion keep revenue growth visible, free cash flow is healthy, and recent guidance raises show the company is executing. The stock trades below its 52-week high but still at a premium multiple; this trade idea lays out a long entry at $252 with a $310 target and $235 stop, sized for a long-term horizo…